Asenapine vs Quetiapine (Seroquel)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Asenapine

Marketed by AbbVie and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00212784 · Phase 3 · completed

This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.

Reported efficacy

Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)

Result source: NCT00212771

Quetiapine (Seroquel)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00305422 · Phase 3 · completed

The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.

Next expected readout: February 2032 · NCT07152184 (registry estimate)

Reported efficacy

Clinical efficacy of both neuroleptics, especially with regard to cognitive deficits and functional brain activation between baseline and week 12: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).

Result source: NCT00305422

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsenapineQuetiapine (Seroquel)
PANSS total, change-21.7 vs -16.2−5.5 vs placebo5 mg BID · wk 6 · n 111NCT01617187
18 other results
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -25.5 vs -17.8 5.0 mg BID · wk 8 · n 79 · Phase 3 · primary NCT01190254
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • -33.4 vs -35.9 wk 6 · n 159 · Phase 3 · primary NCT00882518
CGI-S, change-1.2 vs -1−0.2 vs placebo5 mg BID · wk 6 · n 111NCT01617187
17 other results
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -1.3 vs -0.8 5.0 mg BID · wk 8 · n 79 · Phase 3 · secondary NCT01190254
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.8 vs -2.1 wk 6 · n 194 · Phase 3 · secondary NCT00882518
PANSS response39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
62.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380
PSP, change—Not posted · NCT0021277115.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380
Relapse (% of patients)—Not posted · NCT00212771—Not posted · NCT00305422

PANSS total, change

Asenapine
-21.7 vs -16.2−5.5 vs placebo5 mg BID · wk 6 · n 111NCT01617187
18 other results
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -25.5 vs -17.8 5.0 mg BID · wk 8 · n 79 · Phase 3 · primary NCT01190254
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
Quetiapine (Seroquel)
-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • -33.4 vs -35.9 wk 6 · n 159 · Phase 3 · primary NCT00882518

CGI-S, change

Asenapine
-1.2 vs -1−0.2 vs placebo5 mg BID · wk 6 · n 111NCT01617187
17 other results
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -1.3 vs -0.8 5.0 mg BID · wk 8 · n 79 · Phase 3 · secondary NCT01190254
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
Quetiapine (Seroquel)
-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.8 vs -2.1 wk 6 · n 194 · Phase 3 · secondary NCT00882518

PANSS response

Asenapine
39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
Quetiapine (Seroquel)
62.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380

PSP, change

Asenapine
—Not posted · NCT00212771
Quetiapine (Seroquel)
15.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380

Relapse (% of patients)

Asenapine
—Not posted · NCT00212771
Quetiapine (Seroquel)
—Not posted · NCT00305422
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety

Coverage. Asenapine: 15 of 15 rows · Quetiapine (Seroquel): 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAsenapine
Rows use multiple source trials
Quetiapine (Seroquel)
Rows use multiple source trials
CGI-I
responder rate · % of participants
66.7% (n=111) vs 62.6% (n=99) placebo @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
59.4% (n=96) vs 62.6% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
87.6% (n=194) vs 88.9% (n=190) Chlorpromazine @ 6wkb,c
NCT00882518 · Phase 3 · registry result, not featured evidence
CGI-I
absolute value · score
2.5 vs 3.1 placebo score @ 8wk5.0 mg BIDa,b,c,d
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
2.8 vs 3.1 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
2.5 vs 3 placebo score @ 6wkb,c,d
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS 30%
responder rate · % of participants
25.2% (n=111) vs 19.2% (n=99) placebo @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
14.6% (n=96) vs 19.2% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
57.7% (n=194) vs 66.3% (n=190) Chlorpromazine @ 6wkb,c
NCT00882518 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology
absolute change · score
-10.1 vs -8 placebo score @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
-8.9 vs -8 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-11.6 vs -8.2 placebo score @ 6wkb,c
NCT01810380 · Phase 3 · registry result, not featured evidence
1 other source trial
-12.9 vs -13.9 Chlorpromazine score @ 6wk
NCT00882518 · Phase 3 · registry result, not featured evidence
PANSS Marder Anxiety Depression
absolute change · score
-3.4 vs -3 placebo score @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.9 vs -3 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.6 vs -2.9 placebo score @ 6wkb,c
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought
absolute change · score
-4.3 vs -2.7 placebo score @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
-3.8 vs -2.7 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.8 vs -3.2 placebo score @ 6wkb,c
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative
absolute change · score
-4.7 vs -4 placebo score @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
-3.4 vs -4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.8 vs -3.6 placebo score @ 6wkb,c
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive
absolute change · score
-7.6 vs -6.2 placebo score @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
-6.8 vs -6.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.4 vs -5.7 placebo score @ 6wkb,c
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement
absolute change · score
-1.8 vs -1.1 placebo score @ 6wk5 mg BIDa,b,c
NCT01617187 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.1 vs -1.1 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.8 vs -1.8 placebo score @ 6wkb,c
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Negative Subscale
absolute change · score
-4.9 vs -3.4 placebo score @ 8wk5.0 mg BIDa,b,c,d
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
-4.8 vs -3.4 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-4.5 vs -3.1 placebo score @ 6wkb,c,d
NCT01810380 · Phase 3 · registry result, not featured evidence
1 other source trial
-5.9 vs -6.7 Chlorpromazine score @ 6wk
NCT00882518 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale
absolute change · score
-9.1 vs -6 placebo score @ 8wk5.0 mg BIDa,b,c,d
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
-7.9 vs -6 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-8.1 vs -5.4 placebo score @ 6wkb,c,d
NCT01810380 · Phase 3 · registry result, not featured evidence
1 other source trial
-9.9 vs -11.1 Chlorpromazine score @ 6wk
NCT00882518 · Phase 3 · registry result, not featured evidence
Dropout rate
44.4%5 mg twice dailye
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
16.7%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
54.8%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
1%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
35.2%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
40.1%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
50%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.9%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
17.3%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
33.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
50.4%
NCT00145496 · Phase 3 · registry result, not featured evidence
30.4%
NCT00150176 · Phase 3 · registry result, not featured evidence
15.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
67.7%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
33.3%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
25%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—Seroquel IRe
NCT01213836 · Phase 4 · registry result, not featured evidence
show 7 more results
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
30.4%
NCT00156715 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
20.8%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
19.4%
NCT00882518 · Phase 3 · registry result, not featured evidence
37.8%
NCT00227305 · Phase 3 · registry result, not featured evidence
16.7%
NCT00642369 · Phase na · registry result, not featured evidence
Discontinued due to AEs
22.2%5 mg twice dailye
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
22.3%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
23.6%
NCT01244828 · Phase 3 · registry result, not featured evidence
17%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
17.6%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
0%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
5.1%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
7.5%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
6.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
8.1%
NCT00174265 · Phase 3 · registry result, not featured evidence
17.2%
NCT00145496 · Phase 3 · registry result, not featured evidence
8.2%
NCT00150176 · Phase 3 · registry result, not featured evidence
7.5%
NCT00265343 · Phase 3 · registry result, not featured evidence
11.8%
NCT00156065 · Phase 3 · registry result, not featured evidence
—5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—Seroquel IRe
NCT01213836 · Phase 4 · registry result, not featured evidence
show 7 more results
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
—
NCT00156715 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
2.6%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
4.6%
NCT00882518 · Phase 3 · registry result, not featured evidence
10.5%
NCT00227305 · Phase 3 · registry result, not featured evidence
6.7%
NCT00642369 · Phase na · registry result, not featured evidence
Serious AEs
0%5 mg twice dailye
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
20.4%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
4.4%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.9%
NCT01244828 · Phase 3 · registry result, not featured evidence
5.7%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
2.8%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
12.5%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
3.6%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
2.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
3.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
4.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
12.3%
NCT00145496 · Phase 3 · registry result, not featured evidence
3.1%
NCT00150176 · Phase 3 · registry result, not featured evidence
6.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
14.1%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%Seroquel IRe
NCT01213836 · Phase 4 · registry result, not featured evidence
show 7 more results
0%Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
18.8%
NCT00156715 · Phase 4 · registry result, not featured evidence
1.3%Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
—Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
0%
NCT00882518 · Phase 3 · registry result, not featured evidence
12.1%
NCT00227305 · Phase 3 · registry result, not featured evidence
0%
NCT00642369 · Phase na · registry result, not featured evidence
Most frequent reported AEs
5 mg twice dailye
daytime drowsiness 22.2%
NCT01549041 · Phase 4 · registry result, not featured evidence
show 19 more results
10 mg daily in the evening
daytime drowsiness 0%
NCT01549041 · Phase 4 · registry result, not featured evidence
5/10 mg BID
nasopharyngitis 21.7%
schizophrenia 10.8%
somnolence 10.8%
NCT01142596 · Phase 3 · registry result, not featured evidence
5 mg BID
insomnia 15% (placebo 13.9%)
headache 8.8% (placebo 2%)
anxiety 7.1% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
2.5 mg BID
headache 10.3% (placebo 2%)
insomnia 9.3% (placebo 13.9%)
anxiety 7.2% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21%
somnolence 12.7%
weight increased 12.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
5 mg BID
akathisia 11.4% (placebo 5.2%)
hypoaesthesia oral 10.9% (placebo 3.4%)
insomnia 9.7% (placebo 12.1%)
NCT01098110 · Phase 3 · registry result, not featured evidence
10 mg BID
schizophrenia 13.8% (placebo 24.1%)
somnolence 12.2% (placebo 1.7%)
akathisia 10.5% (placebo 5.2%)
NCT01098110 · Phase 3 · registry result, not featured evidence
accidental overdose 12.5%
acne 12.5%
akathisia 12.5%
NCT01190267 · Phase 3 · registry result, not featured evidence
somnolence 14.8%
headache 6.6%
sedation 5.1%
NCT01190267 · Phase 3 · registry result, not featured evidence
5.0 mg BID
somnolence 17% (placebo 6.9%)
sedation 11.3% (placebo 2%)
insomnia 9.4% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
2.5 mg BID
somnolence 20.4% (placebo 6.9%)
dizziness 7.1% (placebo 1%)
headache 7.1% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
insomnia 10.6%
weight increased 5.9%
headache 2.4%
NCT00174265 · Phase 3 · registry result, not featured evidence
insomnia 17.6%
somnolence 14.8%
headache 13.5%
NCT00145496 · Phase 3 · registry result, not featured evidence
insomnia 20.1% (placebo 24.5%)
somnolence 16% (placebo 17.2%)
weight increased 14.4% (placebo 10.9%)
NCT00150176 · Phase 3 · registry result, not featured evidence
headache 5.2%
influenza 5.2%
schizophrenia 5.2%
NCT00265343 · Phase 3 · registry result, not featured evidence
insomnia 18.5%
headache 10.9%
parkinsonism 10.9%
NCT00156065 · Phase 3 · registry result, not featured evidence
5 mg
dystonia 66.7%
dizziness 33.3%
nausea 33.3%
NCT01206517 · Phase 1 · registry result, not featured evidence
10 mg
hypoaesthesia oral 50%
dizziness 38.9%
dysgeusia 38.9%
NCT01206517 · Phase 1 · registry result, not featured evidence
2.5 mg
sedation 33.3%
dysgeusia 16.7%
hypoaesthesia oral 16.7%
NCT01206517 · Phase 1 · registry result, not featured evidence
e
somnolence 3.2%
delusion 1.6%
dizziness 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
show 5 more results
psychotic disorder 1.6%
sedation 1.6%
sleep disorder 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
dry mouth 43.8%
sedation 43.8%
increased appetite/weight gain 31.3%
NCT00156715 · Phase 4 · registry result, not featured evidence
somnolence 22.2% (placebo 5%)
weight increased 13.1% (placebo 3.7%)
dizziness 11.8% (placebo 0.6%)
NCT01810380 · Phase 3 · registry result, not featured evidence
constipation 25%
dizziness 14.3%
insomnia 12.8%
NCT00882518 · Phase 3 · registry result, not featured evidence
somnolence 30.3%
increased appetite 20%
sedation 18.9%
NCT00227305 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 8 weeks versus 6 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Asenapine

BPRS Total 7.72 score @ 2wk5 mg twice daily
absolute change · score
No placebo or comparator arm
NCT01549041 · Phase 4 · registry result, not featured evidence
show 1 more result
16.08 score @ 2wk10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
Time to Loss of Efficacy 5.82 months5/10 mg BID
time to event · months
Extension (open-label)
No placebo or comparator arm
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 177 days as posted
show 1 more result
12.09 months*5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 368 days as posted
Weight 1.3 vs 0.3 placebo kg @ 6wk5 mg BID
absolute change · kg
NCT01617187 · Phase 3 · registry result, not featured evidence
show 2 more results
1.3 vs 0.3 placebo kg @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0 vs 2.6 Olanzapine kg @ 26wk
NCT00145496 · Phase 3 · registry result, not featured evidence
PANSS Negative -0.5 vs -0.8 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-1.3 vs -1.1 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -1.8 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.3 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -3 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -2.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.72 vs -0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.27 vs -0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.1 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.6 vs -1.8 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.3 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -3 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -3.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS Positive -1.6 vs -1.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-2.8 vs -2.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3.7 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5 vs -4.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.7 vs -5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.5 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.2 vs -5.4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.31 vs -0.85 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.63 vs -0.85 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -3.7 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.1 vs -5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -5.5 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.6 vs -5.4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
Weight 0.25 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT01244828 · Phase 3 · registry result, not featured evidence
BMI 0.07 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT01244828 · Phase 3 · registry result, not featured evidence
HbA1c 0% (n=79) @ 52wk
absolute change · percentage points
No placebo or comparator arm
NCT01244828 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose 0.11 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT01244828 · Phase 3 · registry result, not featured evidence
Fasting Insulin 2.31 uIU/mL @ 52wk
absolute change · uIU/mL
No placebo or comparator arm
NCT01244828 · Phase 3 · registry result, not featured evidence
PANSS Total -11.08 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT01244828 · Phase 3 · registry result, not featured evidence
show 1 more result
-5.48 score
NCT01244828 · Phase 3 · registry result, not featured evidence
CGAS 15 vs 10.2 placebo score @ 8wk5.0 mg BID
absolute change · score
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more result
12.8 vs 10.2 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence

+ 20 further endpoints in the CSV export.

Quetiapine (Seroquel)

Attention Composite Z-score 0.002 standardised units
absolute change · standardised units
No placebo or comparator arm
Post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.098 standardised units
Post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
N-Back Task 2.875 score
absolute change · score
No placebo or comparator arm
ONB post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
show 1 more result
2.897 score
ONB post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
Drinking Days Per 2.7 per week @ 12wk
absolute value · per week
No placebo or comparator arm
NCT00156715 · Phase 4 · registry result, not featured evidence
PANSS-EC -3.9 vs -2.5 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence
Lack of Efficacy 7.19% (n=153) vs 14.91% (n=161) placebo @ 6wk
event rate · % of participants
NCT01810380 · Phase 3 · registry result, not featured evidence
PSP 15.3 vs 9.4 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence
PSP Functional Remission 14.4% (n=146) vs 5.7% (n=157) placebo @ 6wk
responder rate · % of participants
NCT01810380 · Phase 3 · registry result, not featured evidence
PSP Functional 64.4% (n=146) vs 36.3% (n=157) placebo @ 6wk
responder rate · % of participants
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Aggression, Hostility Clusters -4.8 vs -5.4 Chlorpromazine score @ 6wk
absolute change · score
NCT00882518 · Phase 3 · registry result, not featured evidence
PANSS Depression Clusters -1.8 vs -1.7 Chlorpromazine score @ 6wk
absolute change · score
NCT00882518 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Quetiapine (Seroquel)'s landscape